Tyr779
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr779  -  AXL (human)

Site Information
ADCLDGLyALMSRCW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451490

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 6 , 7 , 8 ) , mutation of modification site ( 3 ) , phospho-antibody ( 2 , 4 , 5 ) , western blotting ( 2 , 5 )
Disease tissue studied:
bone cancer ( 6 ) , osteosarcoma ( 6 ) , brain cancer ( 7 ) , astrocytoma ( 7 ) , ganglioglioma ( 4 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 ) , leiomyosarcoma ( 6 ) , cancer, squamous cell carcinoma ( 3 )
Relevant cell line - cell type - tissue:
'stem, breast cancer' ( 5 ) , Azr3 ( 2 ) , Azr4 ( 2 ) , breast cell-breast ( 5 ) , Cor-1 ( 2 ) , COR10 ( 2 ) , HCC827 (pulmonary) ( 2 ) , HeLa (cervical) ( 8 ) , HN (squamous) ( 3 ) , MCF10A1 (epithelial) ( 5 ) , MG63 (bone cell) ( 6 ) , NCI-H1975 (pulmonary) ( 2 ) , PC9 (pulmonary) ( 2 ) , Saos-2 (bone cell) ( 6 ) , SK-LMS-1 (muscle cell) ( 6 ) , U-118MG (glial) ( 7 )

Upstream Regulation
Regulatory protein:
GAS6 (human) ( 5 )
Treatments:
amuvatinib ( 5 ) , osimertinib ( 2 ) , rociletinib ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
glioblastoma ( 4 )

References 

1

Niu X, et al. (2021) Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood 137, 3641-3655
33786587   Curated Info

2

Zhang X, et al. (2021) Alterations in the global proteome and phosphoproteome in third-generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res
33727228   Curated Info

3

McDaniel NK, et al. (2020) AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. Clin Cancer Res
32439698   Curated Info

4

Onken J, et al. (2017) Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival. Oncotarget 8, 50403-50414
28881571   Curated Info

5

Asiedu MK, et al. (2014) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33, 1316-24
23474758   Curated Info

6

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

7

Possemato A (2011) CST Curation Set: 11927; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Moritz A (2010) CST Curation Set: 9059; Year: 2010; Biosample/Treatment: cell line, HeLa/Peroxide; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info